The Latin America, Middle East and Africa PARP Inhibitor Biomarkers Market would witness market growth of 9.9% CAGR during the forecast period (2024-2031).
The Brazil market dominated the LAMEA PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $33.9 Million by 2031. The Argentina market is showcasing a CAGR of 10.8% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 9.5% during (2024 - 2031).
biomarker testing, including it, is increasingly integrated into routine clinical practice across oncology care settings. Healthcare providers recognize the importance of biomarker-guided treatment decisions in optimizing patient outcomes and are incorporating biomarker testing into standard care pathways.
Additionally, Clinical laboratories and molecular diagnostic companies are expanding their testing portfolios to include this, offering healthcare providers access to reliable and comprehensive testing services.
With a higher healthcare budget, Saudi Arabia can invest in expanding its healthcare infrastructure, including hospitals, clinics, and diagnostic facilities. This expansion improves access to healthcare services, including biomarker testing for cancer patients. Increased access to healthcare services leads to higher demand for biomarker testing, including PARP inhibitor biomarkers, thereby driving market growth.
Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $33.9 Million by 2031. The Argentina market is showcasing a CAGR of 10.8% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 9.5% during (2024 - 2031).
biomarker testing, including it, is increasingly integrated into routine clinical practice across oncology care settings. Healthcare providers recognize the importance of biomarker-guided treatment decisions in optimizing patient outcomes and are incorporating biomarker testing into standard care pathways.
Additionally, Clinical laboratories and molecular diagnostic companies are expanding their testing portfolios to include this, offering healthcare providers access to reliable and comprehensive testing services.
With a higher healthcare budget, Saudi Arabia can invest in expanding its healthcare infrastructure, including hospitals, clinics, and diagnostic facilities. This expansion improves access to healthcare services, including biomarker testing for cancer patients. Increased access to healthcare services leads to higher demand for biomarker testing, including PARP inhibitor biomarkers, thereby driving market growth.
Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
List of Key Companies Profiled
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- NeoGenomics Laboratories
- Qiagen N.V
- Agilent Technologies, Inc.
- Merck KGaA
- Bayer AG
- AstraZeneca PLC
- GlaxoSmithKline PLC (GSK)
Market Report Segmentation
By Product- Kits
- Assays
- Breast Cancer
- Ovarian Cancer
- Others
- BRCA 1 & 2 Testing
- HRD Testing
- HRR Testing
- Others
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. LAMEA PARP Inhibitor Biomarkers Market by Product
Chapter 5. LAMEA PARP Inhibitor Biomarkers Market by Application
Chapter 6. LAMEA PARP Inhibitor Biomarkers Market by Services
Chapter 7. LAMEA PARP Inhibitor Biomarkers Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- NeoGenomics Laboratories
- Qiagen N.V
- Agilent Technologies, Inc.
- Merck KGaA
- Bayer AG
- AstraZeneca PLC
- GlaxoSmithKline PLC (GSK)
Methodology
LOADING...
